Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Abstract Immune checkpoint inhibitor (ICI) activates host’s anti-tumor immune response by blocking negative regulatory immune signals. A series of clinical trials showed that ICI could effectively induce tumor regression in a subset of advanced cancer patients. In clinical practice, a main concernin...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-03-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12943-019-0974-6 |
| _version_ | 1828425839121793024 |
|---|---|
| author | Ming Yi Dechao Jiao Shuang Qin Qian Chu Kongming Wu Anping Li |
| author_facet | Ming Yi Dechao Jiao Shuang Qin Qian Chu Kongming Wu Anping Li |
| author_sort | Ming Yi |
| collection | DOAJ |
| description | Abstract Immune checkpoint inhibitor (ICI) activates host’s anti-tumor immune response by blocking negative regulatory immune signals. A series of clinical trials showed that ICI could effectively induce tumor regression in a subset of advanced cancer patients. In clinical practice, a main concerning for choosing ICI is the low response rate. Even though multiple predictive biomarkers such as PD-L1 expression, mismatch-repair deficiency, and status of tumor infiltrating lymphocytes have been adopted for patient selection, frequent resistance to ICI monotherapy has not been completely resolved. However, some recent studies indicated that ICI resistance could be alleviated by combination therapy with anti-angiogenesis treatment. Actually, anti-angiogenesis therapy not only prunes blood vessel which is essential to cancer growth and metastasis, but also reprograms the tumor immune microenvironment. Preclinical studies demonstrated that the efficacy of combination therapy of ICI and anti-angiogenesis was superior to monotherapy. In mice model, combination therapy could effectively increase the ratio of anti-tumor/pro-tumor immune cell and decrease the expression of multiple immune checkpoints more than PD-1. Based on exciting results from preclinical studies, many clinical trials were deployed to investigate the synergistic effect of the combination therapy and acquired promising outcome. This review summarized the latest understanding of ICI combined anti-angiogenesis therapy and highlighted the advances of relevant clinical trials. |
| first_indexed | 2024-12-10T16:37:13Z |
| format | Article |
| id | doaj.art-7d4db46d9590437590e70bbc1b1ff584 |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-12-10T16:37:13Z |
| publishDate | 2019-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-7d4db46d9590437590e70bbc1b1ff5842022-12-22T01:41:21ZengBMCMolecular Cancer1476-45982019-03-0118111210.1186/s12943-019-0974-6Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatmentMing Yi0Dechao Jiao1Shuang Qin2Qian Chu3Kongming Wu4Anping Li5Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou UniversityDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou UniversityAbstract Immune checkpoint inhibitor (ICI) activates host’s anti-tumor immune response by blocking negative regulatory immune signals. A series of clinical trials showed that ICI could effectively induce tumor regression in a subset of advanced cancer patients. In clinical practice, a main concerning for choosing ICI is the low response rate. Even though multiple predictive biomarkers such as PD-L1 expression, mismatch-repair deficiency, and status of tumor infiltrating lymphocytes have been adopted for patient selection, frequent resistance to ICI monotherapy has not been completely resolved. However, some recent studies indicated that ICI resistance could be alleviated by combination therapy with anti-angiogenesis treatment. Actually, anti-angiogenesis therapy not only prunes blood vessel which is essential to cancer growth and metastasis, but also reprograms the tumor immune microenvironment. Preclinical studies demonstrated that the efficacy of combination therapy of ICI and anti-angiogenesis was superior to monotherapy. In mice model, combination therapy could effectively increase the ratio of anti-tumor/pro-tumor immune cell and decrease the expression of multiple immune checkpoints more than PD-1. Based on exciting results from preclinical studies, many clinical trials were deployed to investigate the synergistic effect of the combination therapy and acquired promising outcome. This review summarized the latest understanding of ICI combined anti-angiogenesis therapy and highlighted the advances of relevant clinical trials.http://link.springer.com/article/10.1186/s12943-019-0974-6Immune checkpoint inhibitorPD-1PD-L1CTLA-4VEGFAnti-angiogenesis |
| spellingShingle | Ming Yi Dechao Jiao Shuang Qin Qian Chu Kongming Wu Anping Li Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment Molecular Cancer Immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 VEGF Anti-angiogenesis |
| title | Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment |
| title_full | Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment |
| title_fullStr | Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment |
| title_full_unstemmed | Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment |
| title_short | Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment |
| title_sort | synergistic effect of immune checkpoint blockade and anti angiogenesis in cancer treatment |
| topic | Immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 VEGF Anti-angiogenesis |
| url | http://link.springer.com/article/10.1186/s12943-019-0974-6 |
| work_keys_str_mv | AT mingyi synergisticeffectofimmunecheckpointblockadeandantiangiogenesisincancertreatment AT dechaojiao synergisticeffectofimmunecheckpointblockadeandantiangiogenesisincancertreatment AT shuangqin synergisticeffectofimmunecheckpointblockadeandantiangiogenesisincancertreatment AT qianchu synergisticeffectofimmunecheckpointblockadeandantiangiogenesisincancertreatment AT kongmingwu synergisticeffectofimmunecheckpointblockadeandantiangiogenesisincancertreatment AT anpingli synergisticeffectofimmunecheckpointblockadeandantiangiogenesisincancertreatment |